Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05898399 · ClinicalTrials.gov registry record · Phase 1

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

A Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Artios Pharma.

Active
Registry status
Phase 1
Development phase
220
Enrollment target
7
Study locations

NCT05898399: Active Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Artios Pharma.

NCT05898399 is a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor that is active but no longer recruiting, run by Artios Pharma. The registered enrollment target is 220 participants, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (15% higher). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05898399, a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, is active but no longer recruiting, sponsored by Artios Pharma.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
220 participants
Enrollment target
7
Study locations

Study Summary

This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.

Primary Outcome

Severity of adverse events as assessed by the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

Conditions Studied

Advanced Solid Tumor Metastatic Solid Tumor

Interventions

  • DRUG Olaparib
  • DRUG ART6043

Study Locations (7)

Texas

  • Mary Crowley Cancer Center - Clinic - Dallas
  • The University of Texas - MD Anderson Cancer Center - Houston

Michigan

  • South Texas Accelerated Research Therapeutics (START) - Midwest - Grand Rapids

New York

  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York

Oklahoma

  • Stephenson Cancer Center - Oncology - Oklahoma City

Pennsylvania

  • Jefferson University Hospitals - Kimmel Cancer Center - Philadelphia

Tennessee

  • SCRI oncology partners - Nashville

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2023-06-30
Est. Completion 2026-12-14
Phase Phase 1
Artios Pharma

5 total trials

What the registry record for NCT05898399 still lists

NCT05898399 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (15% higher).

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Olaparib is the first listed.

NCT05898399 lists 7 locations in 6 states (Texas, Michigan, New York).

Frequently Asked Questions

What is clinical trial NCT05898399 about?

NCT05898399 is a clinical study titled "Study of ART6043 in Advanced/Metastatic Solid Tumors Patients". This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.

What is the current status of trial NCT05898399?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2023-06-30. Estimated completion is 2026-12-14.

What conditions does trial NCT05898399 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Metastatic Solid Tumor.

What interventions are being tested in trial NCT05898399?

The interventions under investigation include: Olaparib (DRUG), ART6043 (DRUG).

Who is sponsoring clinical trial NCT05898399?

This trial is sponsored by Artios Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05898399 being conducted?

This trial has 7 study locations across Michigan, New York, Oklahoma, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05898399's enrollment target sits among peer trials

220 55th of 189 higher than 132 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00920972 · 220 participants · Phase 1

    Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

  • NCT01851642 · 220 participants

    Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

  • NCT02582021 · 220 participants

    WISE CVD - Continuation (WISE HFpEF)

  • NCT04067830 · 220 participants · Phase 2

    Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05898399, the US trial registry maintained by the National Library of Medicine. NCT05898399 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.